Douglas Hunt
Patrimonio netto: 945 350 $ in data 31/05/2026
Patrimonio netto: 945 350 $ in data 31/05/2026
Mr. Douglas Hunt is a Chief Regulatory Affairs Officer at Puma Biotechnology, Inc. Mr. Hunt was previously employed as a VP-Regulatory Affairs & Quality Assurance by ArmaGen, Inc., a Vice President-Global Regulatory Affairs by Baxter Healthcare Corp., and an Executive Director-Therapeutic Area by Amgen, Inc. He received his undergraduate degree from the University of Portsmouth.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 13/04/2026 | 131.848 ( 0,26% ) | 945 350 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Consigliere Generale | 01/01/2018 |
| Società | Posizione | Fine |
|---|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Pharmaceuticals: MajorHealth Technology Develops neurological therapies | Consigliere Generale | 01/12/2017 |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Develops, manufactures and distributes hospital supplies and medical technologies | Consigliere Generale | 01/03/2015 |
| AMGEN INC. | Corporate Officer/Principal | 01/07/2008 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Develops, manufactures and distributes hospital supplies and medical technologies | Health Technology |
ArmaGen, Inc.
ArmaGen, Inc. Pharmaceuticals: MajorHealth Technology Develops neurological therapies | Health Technology |
University of Portsmouth
University of Portsmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Puma Biotechnology, Inc.
Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale